We are live on
!
Find out more
VLC
Van Leeuwen & Company Portfolio holdings
AUM
$197M
1-Year Est. Return
44.16%
This Fund
S&P 500
This Quarter
Est. Return
+10.45%
1 Year Est. Return
+44.16%
3 Year Est. Return
+75.42%
5 Year Est. Return
+199.79%
10 Year Est. Return
–
AUM
$159M
AUM Growth
+$10.4M
(+7%)
Cap. Flow
-$1.99M
Cap. Flow
% of AUM
-1.25%
Top 10 Holdings %
Top 10 Hldgs %
43.29%
Holding
83
New
11
Increased
18
Reduced
41
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DexCom
DXCM
|
+$1.88M |
| 2 |
State Street Energy Select Sector SPDR ETF
XLE
|
+$1.72M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.5M |
| 4 |
Parker-Hannifin
PH
|
+$1.44M |
| 5 |
PKST
Peakstone Realty Trust
PKST
|
+$860K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$3.05M |
| 2 |
NextEra Energy
NEE
|
+$1.42M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$1.13M |
| 4 |
MSCI
MSCI
|
+$997K |
| 5 |
Aon
AON
|
+$906K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.24% |
| 2 | Healthcare | 13.36% |
| 3 | Consumer Discretionary | 12.42% |
| 4 | Financials | 9.9% |
| 5 | Communication Services | 9.77% |
Similar funds
SXM
BG
DAM
CC
CWMU
EA
HI
CC
Van Leeuwen & Company's Q2 2023 Portfolio in Review
As of Q2 2023, Van Leeuwen & Company held 83 positions worth $159M, up 7% from $149M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Van Leeuwen & Company's Q2 2023 filing shows 11 new, 18 increased, 41 reduced and 7 closed positions. Its largest new stake was DexCom: 15,579 shares worth $1.98M. The largest sale was AbbVie, an estimated $3.05M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Van Leeuwen & Company's largest Q2 2023 buy was DexCom: 15,579 shares worth $1.98M.
- Van Leeuwen & Company added most to State Street Energy Select Sector SPDR ETF in Q2 2023, an estimated $1.72M increase.
- Van Leeuwen & Company's biggest Q2 2023 reduction was Thermo Fisher Scientific, cutting an estimated $1.13M.
- Van Leeuwen & Company fully exited AbbVie in Q2 2023, selling an estimated $3.05M.
- Van Leeuwen & Company's ten largest holdings make up 43% of its $159M portfolio in Q2 2023.
- Van Leeuwen & Company opened 11 new positions and closed 7 in Q2 2023.
- Van Leeuwen & Company's portfolio value rose 7% quarter-over-quarter to $159M.
Based on Van Leeuwen & Company's 13F filing for Q2 2023, filed 7 Aug 2023.